Lilly Reports Phase 3b Results for Taltz and Zepbound Combination

The headline reports improved and durable efficacy, patient-reported and metabolic outcomes at one year in adults with psoriatic arthritis and obesity. The body is truncated after stating that nearly three times as many patients taking the combination achieved a specified reduction.